A new study called ARAMON shows promising results for using darolutamide alone to treat non-metastatic or oligometastatic castration-sensitive prostate cancer (CSPC), as known as androgen pathway modulator sensitive (APMS), in men who have biochemical recurrence after surgery or radiation. This phase 2 trial enrolled 23 evaluable patients with PSA ≥0.2 ng/mL post-prostatectomy or ≥2 ng/mL […]
The PRINCE trial has delivered final results showing promise for treating metastatic castration-resistant prostate cancer (mCRPC) with the combination of 177Lu-PSMA-617 (Pluvicto) and pembrolizumab. Published in The Lancet Oncology on April 1, 2026 , this single-arm, phase 1b/2 trial enrolled 37 heavily pretreated men (median age 72, 73% prior docetaxel, 100% prior AR inhibitors) who […]
MRT‑2359 is an investigational, orally bioavailable molecular‑glue degrader targeting GSPT1, a protein involved in translation termination. We talked about this new molecule in this article just one month ago, we already have some good news. In prostate cancer it is being studied in combination with androgen‑receptor (AR)‑axis inhibitors, particularly in metastatic castration‑resistant prostate cancer (mCRPC), […]
A new phase 2 EQUIP trial is comparing two different ways of delivering androgen‑suppressive hormone therapy in men with newly diagnosed or recurrent metastatic hormone‑sensitive prostate cancer, focusing on whether transdermal estrogen patches can improve quality of life compared with standard luteinizing hormone‑releasing hormone (LHRH) analogues. The study is designed around two randomized cohorts, each […]
The PARTHENON trial tests AZD4956, an experimental oral drug that blocks SMARCA2, a protein helping cancer cells rearrange their DNA to keep growing. In tumors already “weak” at fixing DNA damage due to homologous recombination deficiency (HRD), shutting down SMARCA2 creates a double hit: cells can’t remodel chromatin or repair errors, leading to collapse. This […]
The AM006 clinical trial, tests HER2 FPBMC anti-CD3 x anti-HER2 bispecific antibody (HER2Bi)-armed activated T cells, in patients with HER2-positive metastatic prostate and breast cancer. For prostate cancer patients, this targets the 20-30% of metastatic cases overexpressing HER2, offering a fresh immune-based option after standard therapies fail. HER2 FPBMC starts with a simple blood draw […]
64Cu-SAR-bisPSMA represents a next-generation PSMA-targeted PET imaging agent for prostate cancer, demonstrating superior lesion and patient detection in the Phase 2 Co-PSMA trial announced in February 2026. In this head-to-head study of 50 patients with biochemical recurrence (BCR) after prostatectomy (PSA 0.2-0.75 ng/mL), Cu-64 SAR-bisPSMA more than doubled mean lesions per patient at 1.26 (63 […]
Igermetostat (XNW5004), a selective EZH2 inhibitor, pairs effectively with enzalutamide in metastatic castration-resistant prostate cancer after prior novel hormone therapy, based on phase 1b/2 results. EZH2 inhibition reverses enzalutamide resistance through epigenetic changes in castration-resistant prostate cancer models. The study endpoints focused on recommended phase 2 dose, safety, and radiographic progression-free survival. Eighty-four patients enrolled […]
The UPLIFT trial is a phase 1/2 study testing a new combo for metastatic castrate-resistant prostate cancer. Researchers at the University of California, San Francisco, designed this trial to boost the power of 177Lu-PSMA-617, a targeted radiation drug called a radioligand therapy. That drug latches onto PSMA, a protein stamped all over prostate cancer cells, […]
MRT-2359 is a daily pill that destroys certain cancer-driving proteins, including the androgen receptor (AR), MYC, and Cyclin D1, by blocking a key step in how cells read genetic instructions. This approach targets metastatic castration-resistant prostate cancer (mCRPC), where AR mutations in the ligand-binding domain (LBD) allow tumors to grow despite hormone-blocking drugs like enzalutamide. […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy